Suppr超能文献

通过离子激流DNA测序检测到人类肺癌肿瘤中EGFR、KRAS和TP53基因频繁发生突变。

Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.

作者信息

Cai Xin, Sheng Jianhui, Tang Chuanning, Nandakumar Vijayalakshmi, Ye Hua, Ji Hong, Tang Haiying, Qin Yu, Guan Hongwei, Lou Feng, Zhang Dandan, Sun Hong, Dong Haichao, Zhang Guangchun, Liu Zhiyuan, Dong Zhishou, Guo Baishuai, Yan He, Yan Chaowei, Wang Lu, Su Ziyi, Li Yangyang, Jones Lindsey, Huang Xue F, Chen Si-Yi, Wu Taihua, Lin Hongli

机构信息

The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.

San Valley Biotechnology Incorporated, Beijing, China.

出版信息

PLoS One. 2014 Apr 23;9(4):e95228. doi: 10.1371/journal.pone.0095228. eCollection 2014.

Abstract

Lung cancer is the most common malignancy and the leading cause of cancer deaths worldwide. While smoking is by far the leading cause of lung cancer, other environmental and genetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive lung cancer molecular profile is essential for developing more effective, tailored therapies. Until recently, personalized DNA sequencing to identify genetic mutations in cancer was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 76 human lung cancer samples. The sequencing analysis revealed missense mutations in KRAS, EGFR, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.

摘要

肺癌是全球最常见的恶性肿瘤,也是癌症死亡的主要原因。虽然吸烟是肺癌的主要病因,但其他环境和遗传因素也会影响癌症的发生和发展。由于在个体癌症样本中观察到独特的突变模式,因此识别和表征独特的肺癌分子特征对于开发更有效、更具针对性的治疗方法至关重要。直到最近,用于识别癌症中基因突变的个性化DNA测序仍不切实际且成本高昂。新一代DNA测序技术的最新进展,如基于半导体的Ion Torrent测序平台,使DNA测序在成本和时间上更具效益,结果也更可靠。使用Ion Torrent Ampliseq癌症检测板,我们对45个癌症相关基因的737个位点进行了测序,以识别76个人类肺癌样本中的基因突变。测序分析揭示了不同组织学类型的乳腺癌样本中KRAS、EGFR和TP53基因的错义突变。因此,本研究证明了对个体人类癌症进行测序的必要性,以便开发个性化药物或联合疗法,有效地针对个体乳腺癌特异性突变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/3997391/645063811f53/pone.0095228.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验